麦趣尔(002719) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2025 was ¥168,876,510.33, an increase of 0.35% compared to the same period last year[4] - The net profit attributable to shareholders was -¥34,637,135.59, a decrease of 53.42% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥38,252,466.03, an increase of 100.54% compared to the previous year[4] - Total operating revenue for the current period is CNY 463,182,078.60, a decrease of 2.66% from CNY 476,441,743.89 in the previous period[23] - Net profit for the current period is CNY -33,509,117.35, an improvement from CNY -87,947,424.10 in the previous period[24] - The company reported a total comprehensive loss of CNY -33,509,117.35 for the current period, improving from CNY -87,947,424.10 in the previous period[24] Earnings Per Share - The basic and diluted earnings per share were both -¥0.1989, reflecting a 53.48% increase year-on-year[6] - Basic and diluted earnings per share are both CNY -0.19, compared to CNY -0.4994 in the previous period[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,089,997,527.99, a slight increase of 0.18% from the end of the previous year[6] - The total assets of the company amounted to approximately CNY 1,089.99 million, showing a slight increase from CNY 1,088.05 million at the beginning of the period[19] - Total liabilities amount to CNY 905,172,249.51, an increase from CNY 869,826,570.97 in the previous period[21] - The company’s total liabilities increased, with current liabilities reaching CNY 122.51 million in contract liabilities, up from CNY 112.83 million[19] Cash Flow - Cash and cash equivalents decreased by ¥12,936,700, a decline of 40.75%, primarily due to reduced operating cash inflows[12] - The company’s cash and cash equivalents decreased significantly to CNY 18.81 million from CNY 31.74 million, indicating a liquidity contraction[19] - The net cash flow from operating activities was -3,844,616.74, compared to 4,039,646.59 in the previous period[30] - Cash inflow from operating activities is CNY 563,949,182.10, a decrease of 6.34% from CNY 602,206,006.40 in the previous period[28] - Cash outflow from operating activities totals CNY 567,793,798.84, down from CNY 598,166,359.81 in the previous period[28] Accounts Receivable and Payable - Accounts receivable increased by ¥42,028,100, a growth of 43.63%, attributed to uncollected sales[12] - Accounts payable rose slightly to CNY 430.40 million from CNY 423.42 million, indicating stable supplier relationships[19] Inventory and Other Assets - Inventory decreased by ¥19,225,700, a decline of 35.29%, mainly from the sale of consumable biological assets[12] - The non-current assets totaled CNY 843.99 million, down from CNY 871.26 million, primarily due to a decrease in fixed assets[20] - The company reported a significant increase in prepayments, which rose to CNY 26.47 million from CNY 12.18 million, suggesting proactive inventory management[19] Financing Activities - Short-term borrowings increased by ¥32,481,500, primarily due to new short-term loans[12] - Short-term borrowings increased to CNY 50.00 million from CNY 17.52 million, reflecting a higher reliance on debt financing[19] - The company received 41,500,000.00 in cash from borrowings, a significant increase from 9,000,000.00 in the previous period[30] - The company paid 36,288,000.00 in cash for debt repayment, compared to 20,410,000.00 in the previous period[30] Strategic Focus - The company is focusing on enhancing its product offerings and market expansion strategies, although specific new products or technologies were not detailed in the report[15]